PIVENS及其相关的后续研究与非酒精性脂肪性肝病治疗的未来方向

被引：7

作者：

曾民德

机构：

[1] 上海交通大学医学院附属仁济医院,上海市消化疾病研究所,上海市脂肪性肝病诊治研究中心

来源：

肝脏 | 2014年 / 19卷 / 01期

关键词：

NAFLD; AMPK; 激活剂; 新靶点; 联合治疗; PIVENS; 炎症体; 肝脂肪变; 未来方向;

D O I：

10.14000/j.cnki.issn.1008-1704.2014.01.023

中图分类号：

R575.5 [肝代谢障碍];

学科分类号：

1002 ; 100201 ;

摘要：

<正>自从非酒精性脂肪性肝炎临床研究网络病理学会(NASH-CRN)发起的吡格列酮(PIOG)或维生素E(Vit E)治疗NASH(PIVENS)的随机对照临床试验(RCT)一文发表后[1],又有多项与PIVENS相关的后续研究报道。如何探索NAFLD治疗新靶点及发展多层面药物干预顿时成为热点话题。本文以此为视角,试谈NAFLD治疗的未来方向。一、PIVENS研究及对PIVENS研究的评估PIVENS研究针对胰岛素抵抗(IR)和氧化应激两个主要治疗靶向,应用PIOG或Vit E对247例非糖尿病(DM)的NASH患者进行RCT,疗程2年。该研究以NAFLD活动度评分(NAS)为主要终点评估。结果显示,两药物组降低NAS 2

引用

页码：53 / 56

页数：4

共 17 条

[1] Novel therapeutic targets for nonalcoholic fatty liver disease [J].

Eguchi, Akiko ;

Povero, Davide ;

Alkhouri, Naim ;

Feldstein, Ariel E. .

EXPERT OPINION ON THERAPEUTIC TARGETS, 2013, 17 (07) :773-779

[2]

Mitochondrial dysfunction in non-alcoholic fatty liver disease and insulin resistance: Cause or consequence?[J] . C. Garc&iacute,a-Ruiz,A. Baulies,M. Mari,P. M. Garc&iacute,a-Rov&eacute,s,J. C. Fernandez-Checa.Free Radical Research . 2013 (11)

[3]

Pentoxifylline decreases oxidized lipid products in nonalcoholic steatohepatitis: New evidence on the potential therapeutic mechanism[J] . Claudia O. Zein,Rocio Lopez,Xiaoming Fu,John P. Kirwan,Lisa M. Yerian,Arthur J. McCullough,Stanley L. Hazen,Ariel E. Feldstein.Hepatology . 2012 (4)

[4]

Relationship between adipose tissue insulin resistance and liver histology in nonalcoholic steatohepatitis: A pioglitazone versus vitamin E versus placebo for the treatment of nondiabetic patients with nonalcoholic steatohepatitis trial follow‐up study[J] . Lauren N. Bell,Jiangxia Wang,Sriya Muralidharan,Sadhana Chalasani,Allison M. Fullenkamp,Laura A. Wilson,Arun J. Sanyal,Kris V. Kowdley,Brent A. Neuschwander‐Tetri,Elizabeth M. Brunt,Arthur J. McCullough,Nathan M. Bass,Anna Mae Diehl,Aynur Una

[5]

Association between diabetes, family history of diabetes, and risk of nonalcoholic steatohepatitis and fibrosis[J] . Rohit Loomba,Maria Abraham,Aynur Unalp,Laura Wilson,Joel Lavine,Ed Doo,Nathan M. Bass.Hepatology . 2012 (3)

[6]

Therapeutic Strategies in Inflammasome Mediated Diseases of the Liver[J] . Rafaz Hoque,Yoram Vodovotz,Wajahat Mehal.Journal of Hepatology . 2012

[7]

The Gut Microbiota and the Liver Pathophysiological and Clinical Implications[J] . Eamonn M .M. Quigley,Catherine Stanton,Eileen F. Murphy.Journal of Hepatology . 2012

[8]

The mitochondrial carnitine/acylcarnitine carrier: Function, structure and physiopathology[J] . Cesare Indiveri,Vito Iacobazzi,Annamaria Tonazzi,Nicola Giangregorio,Vittoria Infantino,Paolo Convertini,Lara Console,Ferdinando Palmieri.Molecular Aspects of Medicine . 2011 (4)

[9]

Therapeutic trials in nonalcoholic steatohepatitis: Insulin sensitizers and related methodological issues[J] . Vlad Ratziu,Stephen Caldwell,Brent A. Neuschwander‐Tetri.Hepatology . 2010 (6)

[10]

Clinical, laboratory and histological associations in adults with nonalcoholic fatty liver disease[J] . Brent A. Neuschwander‐Tetri,Jeanne M. Clark,Nathan M. Bass,Mark L. Van Natta,Aynur Unalp‐Arida,James Tonascia,Claudia O. Zein,Elizabeth M. Brunt,David E. Kleiner,Arthur J. McCullough,Arun J. Sanyal,Anna Mae Diehl,Joel E. Lavine,Naga Chalasani,Kris V. Kowdley.Hepatology . 2010 (3)

← 1 2 →